The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
| Jude Jonassaint, RN | |
| 919-219-7481 | |
| [email protected] |
| Nydia Chien, MSN | |
| [email protected] |
> 18 Years
Phase 3
Interventional
All
Biological
Other
Age 18 years or older
Diagnosis of SCD: homozygous sickle cell disease, hemoglobin-SC, Sβ-thalassemia, hemoglobin-SO or hemoglobin-SD.
Patients not on a chronic exchange transfusion program for at least 60 days.
If patients are on a SCD drug (e.g. hydroxyurea, glutamine, or P-selectin inhibitors), the doses must be stable for at least 60 days prior to randomization.
Any one of the following vasculopathy biomarker clinical results (a, b, c, d or e) measured in the last 24 months before randomization that indicates a high-risk patient:
Both a TRV 2.5- <3.0 m/sec and NT-proBNP plasma level ≥ 160 pg/mL, TRV ≥ 3.0 m/sec, Both a mean pulmonary artery pressure (PAP) by right heart catheterization 20-24 mmHg and NT-proBNP plasma level ≥ 160 pg/mL, Mean PAP by right heart catheterization ≥ 25 mmHg, Chronic kidney disease (CKD) due to SCD with abnormal measures on 2 separate occasions as defined by: macroalbuminuria (albumin to creatinine ratio (ACR) >300 mg/g) or proteinuria (protein to creatinine ratio >30 mg/mmol), or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. (It is recommended that local laboratories use Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation without ethnic factors when estimating and reporting GFR). Clinical results of these biomarkers measured locally at sites within 24 months prior to randomization are acceptable to determine eligibility. TRV, PAP, NT-proBNP, albumin to creatinine ratio, protein to creatinine ratio, or eGFR values must be measured in a steady state (defined as measured ≥ 14 days since an acute care pain event) on different days. vi. Written informed consent obtained from patient to participate in the trial.
RBC alloimmunization resulting in inability of blood bank to obtain compatible components for chronic exchange transfusions
Previous history of hyper-hemolysis syndrome
Previous history of severe transfusion reaction resulting in renal failure or due to serious complications such as hypotension or respiratory distress
More than 10 vaso-occlusive episodes in the past 12 months requiring admission to a hospital to receive treatment.
Religious objection to receiving blood transfusion
Diagnosis of ischemic stroke within the past 6 months
Clinical evidence of liver failure or advanced cirrhosis or any co-existing medical condition that in the Investigator’s judgement will substantially increase the risk associated with the patient’s participation in the trial
Women of childbearing potential who have a positive pregnancy test at baseline